The resistance of CRC to Cetuximab or Panitumumab can also be mediated by the activity of other HER family members; for example, by the overexpression of the HER2 gene, an event with quite a low frequency (2%) can occur [14]. The gene discussed is ERBB2; the disease is colorectal carcinoma.